THERAPY DOSSIER · th-26e149678f86

Human umbilical cord blood-derived late outgrowth endothelial progenitor cells (late EPC) or mesenchymal stem cells (MSC)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06798727 ↗PHASE2active not recruiting

Long-term follow-up of subjects receiving SMUP-IA-01 or active control

Knee Osteoarthritis

Enrolment: 84 · Results not recorded

NCT07131306 ↗PHASE2not yet recruiting

MODALITY-level surrogate: umbilical cord MSC therapy in non-viral acute-on-chronic liver failure

Acute-On-Chronic Liver Failure

Enrolment: 100 · Results not recorded

NCT07212335 ↗EARLY_PHASE1recruiting

Umbilical cord blood-derived MSC for long-term cytopenia after CAR-T therapy

Immune Effector Cell Associated Hematotoxicity

Enrolment: 15 · Results not recorded

NCT04037345 ↗PHASE1completed

SMUP-IA-01, umbilical cord blood MSC derived product, in knee osteoarthritis

Knee Osteoarthritis

Enrolment: 12 · Results not recorded

NCT02054208 ↗PHASE1|PHASE2completed

Intraventricular NEUROSTEM (human umbilical cord blood derived MSC) versus placebo in Alzheimer's disease

Alzheimer's Disease

Enrolment: 46 · Results not recorded

NCT06078059 ↗NAcompleted

Cultured allogeneic umbilical cord blood MSC in knee osteoarthritis

Osteoarthritis, Knee

Enrolment: 30 · Results not recorded

NCT01033552 ↗PHASE1|PHASE2completed

MODALITY-level surrogate: allogeneic stem cell transplantation and off-the-shelf MSC in severe epidermolysis bullosa

Epidermolysis Bullosa

Enrolment: 32 · Results not recorded

NCT04992832 ↗PHASE1|PHASE2completed

MODALITY-level surrogate: umbilical cord MSC infusion in heart failure with reduced ejection fraction

Heart Failure, Systolic

Enrolment: 40 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26551883 ↗2015Reported benefit

Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair.

RatIschaemia-reperfusionCardiacSprague-Dawley for functional studies and nude rats for mechanistic studiesmaleintramyocardial injection into the border zone of the ischaemic heart5 x 10^5 EPC or MSC in 50 microlitres of phosphate buffered…1 h after myocardial infarction

Model: Myocardial infarction by ligation of the left anterior descending coronary artery

Both late endothelial progenitor cells and mesenchymal stem cells improved ejection fraction, fractional shortening, wall thickness and capillary density and reduced apoptosis compared with vehicle, with fibrosis reduced only in the endothelial progenitor cell group.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.82. Machine-extracted fields require source verification.

Loading the evidence…